Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thyroid iodide accumulation via the sodium/iodide symporter (NIS; SLC5A5) has been the basis for the longtime use of radio-iodide in the diagnosis and treatment of thyroid cancers.
|
24052075 |
2013 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The sodium iodide symporter (NIS) mediates iodide uptake in thyroid cells and enables the effective radioiodide treatment of thyroid cancers.
|
12699587 |
2003 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radioiodine whole body scan (WBS), related to sodium iodide symporter (NIS) function, is widely used to detect recurrence/metastasis in postoperative patients with thyroid cancer.
|
28386277 |
2017 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In principle, undifferentiated thyroid cancers as well as nonthyroid cancers can concentrate and, thus, be treated with radioiodine after transfection with the human sodium iodide symporter (hNIS) gene.
|
21797672 |
2011 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NIS is clinically very relevant because it allows the treatment with radioiodine of thyroid cancer patients.
|
24708099 |
2014 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The lack of Na(+)/I(-) symporter (NIS) gene expression in some thyroid cancer patients has been a major hurdle that limits the efficacy of standard radioactive iodide therapy.
|
18202121 |
2008 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both up- and down-regulation of NIS gene expression have been reported in thyroid cancer using several different methods.
|
11301345 |
2001 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Abundant sodium/iodide symporter protein expression in thyroid cancer cells under these conditions was confirmed by immunofluorescent microscopy.
|
26751190 |
2016 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TSH stimulation of sodium iodide symporter (NIS) expression in thyroid cancer promotes radioiodine uptake and is required to deliver an effective treatment dose.
|
18762555 |
2008 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NIS is a target for radioiodide imaging and therapeutic ablation of thyroid carcinomas and has the potential for similar use in breast cancer treatment.
|
15472226 |
2004 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In mouse models of thyroid cancer, selective mitogen-activated protein kinase (MAPK) pathway antagonists increase the expression of the sodium-iodide symporter and uptake of iodine.Their effects in humans are not known.
|
23406027 |
2013 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study explored the combined cytotoxic effects of adenovirus-mediated CD and NIS under the control of the progression elevated gene-3 (<i>PEG-3</i>) promoter (Ad-PEG-3-CD-NIS) with Na<sup>131</sup>I/5-FC against the human thyroid cancer TT cell line <i>in vitro</i>.
|
29344184 |
2017 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death.
|
29561759 |
2018 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elucidation of the regulation of human sodium-iodide symporter (hNIS) gene expression is critical to understanding its effects on iodide concentration abilities of thyroid and thyroid carcinomas.
|
9492156 |
1998 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Enhancement of <sup>211</sup>At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer.
|
30796173 |
2019 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radioiodide uptake (RAIU) in thyroid follicular epithelial cells, mediated by a plasma membrane transporter, sodium iodide symporter (NIS), provides a first step mechanism for thyroid cancer detection by radioiodide injection and effective radioiodide treatment for patients with invasive, recurrent, and/or metastatic thyroid cancers after total thyroidectomy.
|
12477251 |
2002 |
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Expression of the Na+/I- symporter (NIS) gene was investigated by RT-PCR in a selected series of 26 primary thyroid carcinomas (19 papillary, 5 follicular, and 2 anaplastic).
|
9661633 |
1998 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The increased NIS expression and reduced PDS expression may make radioiodine therapy more effective in patients with thyroid cancer, especially when the tumors have no or low uptake of radioiodine.
|
12490845 |
2002 |
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Sodium/iodide symporter (NIS) is a key protein in iodide transport by thyroid cells and this activity is a prerequisite for effective radioiodide treatment of thyroid cancer.
|
12475396 |
2002 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The sodium/iodide symporter (NIS) is involved in iodide uptake and has been used for the diagnosis and treatment of thyroid cancer.
|
26115738 |
2015 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NIS-mediated iodide uptake in thyroid cells is the basis for targeted radionuclide imaging and treatment of differentiated thyroid carcinomas and their metastases.
|
23404856 |
2013 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS.
|
15062578 |
2003 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Methylation of thyroid-specific genes, such as those for sodium/iodide symporter and thyroid-stimulating hormone receptor, is also common in thyroid cancer.
|
16946009 |
2007 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Noninvasive imaging of iodide uptake via the sodium/iodide symporter (NIS) has received great interest for evaluation of thyroid cancer and reporter imaging of NIS-expressing viral therapies.
|
29198608 |
2018 |
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Strategies to restore iodide uptake in thyroid cancer include the exploration of hNIS gene transfer into hNIS defective thyroid cancer.
|
11573141 |
2001 |